Targeted therapy extends progression-free survival of patients with advanced ovar... ( PHILADELPHIA PA (December 28 2011)T...)

Targeted therapy extends progression-free survival of patients with advanced ovarian cancer

Date:12/28/2011

PHILADELPHIA, PA (December 28, 2011)Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic Oncology Group (GOG) showed that a targeted therapy called bevacizumab (Avastin) effectively delayed the progression of advanced ovarian cancer. Patients with newly diagnosed advanced ovarian cancer now typically undergo surgery and chemotherapy, but the new research suggests an additional avenue of treatment. The results of the trial appear in the December 29 issue of the New England Journal of Medicine.

"This approach can be looked upon as a third major component of treatment for ovarian cancer and related malignancies," says Robert A. Burger, MD, lead investigator on the GOG study and director of the Women's Cancer Center at Fox Chase Cancer Center. "We've had the combination of surgical management and cytotoxic chemotherapy for many years, but we haven't really seen anything else in terms of a fundamental class of treatment. This represents a new way for us to control the disease."

The placebo-controlled study, which was sponsored by the National Cancer Institute, enrolled 1,873 patients with previously untreated advanced disease from 336 sites, primarily in the United States, but also in Canada, South Korea, and Japan. The patients either had stage III ovarian cancer that could not be entirely removed with surgery, or stage IV disease, and were randomly assigned to one of three groups. For patients who received bevacizumab with chemotherapy followed by bevacizumab for up to an additional 10 months, the median time until their cancer progressed was 14.1 months, compared to 10.3 months for patients in the control group, who received chemotherapy with a placebo and then continued with a placebo. The net effect was a 28% reduction in the risk of disease of ovarian cancer p
'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. Targeted delivery of losartan reduces liver inflammation and scarring
2. Gene-Targeted Cancer Fix Could Be a Breakthrough
3. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
4. Targeted agent blocked growth of deadly brain cancer in preclinical studies
5. Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients
6. New targeted therapy effective in treating advanced prostate cancer
7. Gene-Targeted Therapy Might Help Prevent Paralysis
8. Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days
9. Drug in new class of targeted therapies shows early promise against blood-related cancers
10. Women Smokers Targeted on World No Tobacco Day
11. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers

Post Your Comments:

(Date:5/21/2013)... Diehard soccer fans will definitely want to see a ... between Manchester City and Chelsea FC at Busch ... teams are highly decorated in the English Premiere League of ... Busch Stadium, home of the St. Louis Cardinals, a professional ... a professional sporting event and non-baseball game will be held ...

(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay ... life, but some of the changes brought about by ... diabetes. New research has found that people with ... percent higher risk of having a severe low blood ... compared to people with diabetes who aren,t depressed. ...

(Date:5/21/2013)... Philosophical Society (APS) has awarded New York University neuroscientist ... in recognition of his "pioneering work on the neuroscience ... University,s Center for Neural Science, is the second NYU ... yearsJoseph LeDoux received the honor in 2011 in recognition ... emotional learning, particularly fear learning, and fear memory." ...

(Date:5/21/2013)... Representatives with Hammerhead Bicycles announced today that their re-launched bike ... achieved its overall goal of becoming a standalone brand. , ... Bicycles from a house brand to a standalone bike brand,” ... that the bike shop will go forward as Switchback ... 29er and 650b. , “The bike shop will ...

(Date:5/21/2013)... major Ohio universities and four hospitals have joined with ... collaborative research program aimed exclusively at finding the unknown ... to invest $10 million in the program over five ... Center -- Ohio Collaborative is a unique research enterprise," ... of Dimes. "This new transdisciplinary, team-based research model will ...

Breaking Medicine News(10 mins):Health News:Manchester City vs. Chelsea FC Tickets: Cheap Concert Tickets has Slashed Prices on Manchester City vs. Chelsea FC Tickets at Busch Stadium in St. Louis, MO 2 Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2 Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3 Health News:NYU's Movshon receives Lashley Award for his research on the neuroscience of vision 2 Health News:Hammerhead Bicycles Now a Standalone Brand 2 Health News:New multi-million dollar research center aims to solve the mystery of premature birth 2 Health News:New multi-million dollar research center aims to solve the mystery of premature birth 3

[0] Manchester City vs. Chelsea FC Tickets: Cheap Concert Tickets has Slashed Prices on Manchester City vs. Chelsea FC Tickets at Busch Stadium in St. Louis, MO [0] Depression May Raise Low Blood Sugar Risk in Diabetics [0] NYU's Movshon receives Lashley Award for his research on the neuroscience of vision [0] Hammerhead Bicycles Now a Standalone Brand [0] New multi-million dollar research center aims to solve the mystery of premature birth

... Tanaka, president and CEO of Menicon Co., Ltd. ... was appointed as Singapore,s Honorary Consul-General in Nagoya, ... Singapore. The appointment was effective April 20, 2009. ... corporate headquarters in Nagoya.(Photo: http://www.newscom.com/cgi-bin/prnh/20090508/PR34572 ...

... OAK BROOK, Ill., May 7 The University HealthSystem ... 3-year agreement to one supplier, Sodexo Inc., based in ... which has 2 optional 1-year renewal periods, became effective ... of comprehensive management solutions for food and nutrition services ...

... Congress to Make Health Reform Work for ChildrenSTANFORD, Calif., ... Stanford is joining the National Association of Children,s ... grassroots mobilization campaign asking Congress and the Obama Administration ... "Our hospital is extraordinarily proud to be taking ...

... 7 MedQuist Inc., (Nasdaq: MEDQ ) a ... technology-enabled clinical documentation workflow, today announced its unaudited operating results ... the first quarter of 2009 was $6.9 million, an increase ... a loss of $4.4 million was reported. Earnings per share ...

... 7 Trey Anastasio, lead singer of the rock band ... Wednesday, May 6, to participate in a day-long celebration marking ... National Association of Drug Court Professionals (NADCP) in calling for ... Mr. Anastasio recognized over fifteen members of Congress for their ...

... statement from Georges C. Benjamin, MD, FACP, FACEP (E), ... Public Health Association (APHA) joins other leading health organizations ... Obama,s FY 2010 budget."Of particular note is the $635 ... to finance health reform and ensure that we all ...

Dr. Tanaka Appointed as Honorary Consul-General by Republic of Singapore University HealthSystem Consortium Selects Sodexo to Provide Food and Nutrition Services Lucile Packard Children's Hospital at Stanford to Raise Its Voice for Kids in Health Care Reform Debate MedQuist Reports First Quarter 2009 Results Phish Frontman Trey Anastasio Visits Capitol Hill to Support Drug Courts and Calls on Congress to Put a Drug Court Within Reach of Every American in Need APHA Applauds Health Reform Fund and Other Health Investments in Budget

(Date:5/21/2013)... Mass. , May 21, 2013 /PRNewswire/ ... research and advisory firms for pharmaceutical and ... an emerging agent on key efficacy endpoints, ... progression, has the most influence over surveyed ... advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast cancer. ...

(Date:5/21/2013)... , May 21, 2013 Hurel Corporation ("Hurel"), ... microfluidic cell-based assay platforms, today announced the appointment of ... to the Company,s Board of Directors. Dr. MacDonald is ... the Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical ... by Merck & Co. in 2009. Over ...

(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue: ... Coherence Tomography (OCT) http://www.reportlinker.com/p01187977/Global-Markets-and-Technologies-for-Optical-Coherence-Tomography-OCT.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ... BCC,s aim ... synopsis of the current and future characteristics ...

[0] Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer [0] Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors [0] Global Markets and Technologies for Optical Coherence Tomography (OCT)

... treating the diabetes patient, doctors discussed how a ... not enough to reveal an individual,s risk for ... Clinical Endocrinologists (AACE) 18th Annual Meeting & Clinical ... "We need to be more aggressive in treating ...

... Corporation (Nasdaq: BPUR ) announced ... U.S. Naval Medical Research Center (NMRC) by letter that it ... Hemopure(R) [hemoglobin glutamer -- 250 (bovine)] under a proposed protocol ... announced, the study, "Restore Effective Survival in Shock" (RESUS) was ...

Cached Medicine Technology:Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient 2 U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold 2 U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold 3

Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold

Reusable Components Compatible with VERSASTEP™ Reposable Access System....

The VersaStep™ 5 mm and VersaStep™ PLUS Reposable system components for creating each access port are supplied in separate packages....

... VERSASTEP™ Plus Long Instrument for ... ,The VERSASTEP™ Plus Long Instrument ... a unique endoscopic entry device ... procedures. It is used to ...

... Step™ and Mini Step™ device components are supplied ... Single Use System is supplied sterile in 2/3, ... in various configurations and combinations. They are used ... needle and the Step™ radially Expandable Sleeve. The ...

Medicine Products:

Reusable Components VersaStep™ Reposable Powershield™ (Reusable Radiolucent Cannulae - Short Length)VersaStep™ Plus Long Instrument with 150 mm Working Length STEP™ Short Instruments